相似文献
1
Progress toward the clinical application of patient-specific pluripotent stem cells.
J Clin Invest. 2010 Jan;120(1):51-9. doi: 10.1172/JCI40553.
2
Therapeutic application of stem cell technology toward the treatment of Parkinson's disease.
Biol Pharm Bull. 2013;36(2):171-5. doi: 10.1248/bpb.b12-00929.
3
Reprogrammed cells for disease modeling and regenerative medicine.
Annu Rev Med. 2013;64:277-90. doi: 10.1146/annurev-med-050311-163324.
4
Reprogramming therapeutics: iPS cell prospects for neurodegenerative disease.
Neuron. 2009 Feb 12;61(3):337-9. doi: 10.1016/j.neuron.2009.01.024.
5
Current progress and prospects of induced pluripotent stem cells.
Sci China C Life Sci. 2009 Jul;52(7):622-36. doi: 10.1007/s11427-009-0092-6. Epub 2009 Jul 30.
6
Disease-specific pluripotent stem cells.
Korean J Pediatr. 2010 Aug;53(8):786-9. doi: 10.3345/kjp.2010.53.8.786. Epub 2010 Aug 31.
7
Potential application of induced pluripotent stem cells in cell replacement therapy for Parkinson's disease.
CNS Neurol Disord Drug Targets. 2011 Jun;10(4):449-58. doi: 10.2174/187152711795563994.
8
Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
Brain Res. 2016 May 1;1638(Pt A):30-41. doi: 10.1016/j.brainres.2015.09.023. Epub 2015 Sep 28.
9
Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons.
Science. 2008 Aug 29;321(5893):1218-21. doi: 10.1126/science.1158799. Epub 2008 Jul 31.
10
Advances in culture and manipulation of human pluripotent stem cells.
J Dent Res. 2013 Nov;92(11):956-62. doi: 10.1177/0022034513501286. Epub 2013 Aug 9.
引用本文的文献
1
The novel combination of small-molecule inhibitors increases the survival and colony formation capacity of human induced pluripotent stem cells after single-cell dissociation.
Sci Prog. 2025 Apr-Jun;108(2):368504251330956. doi: 10.1177/00368504251330956. Epub 2025 May 13.
2
Forty Years of the Use of Cells for Cartilage Regeneration: The Research Side.
Pharmaceutics. 2024 Dec 22;16(12):1622. doi: 10.3390/pharmaceutics16121622.
3
Downregulation of the silent potassium channel Kv8.1 increases motor neuron vulnerability in amyotrophic lateral sclerosis.
Brain Commun. 2024 Jun 11;6(3):fcae202. doi: 10.1093/braincomms/fcae202. eCollection 2024.
4
Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.
Stem Cell Res Ther. 2024 Jun 18;15(1):170. doi: 10.1186/s13287-024-03782-5.
5
Stem Cells Reprogramming in Diabetes Mellitus and Diabetic Complications: Recent Advances.
Curr Diabetes Rev. 2025;21(4):21-37. doi: 10.2174/0115733998275428231210055650.
6
Strategies targeting endoplasmic reticulum stress to improve Parkinson's disease.
Front Pharmacol. 2023 Nov 10;14:1288894. doi: 10.3389/fphar.2023.1288894. eCollection 2023.
7
Intranasally administered extracellular vesicles from human induced pluripotent stem cell-derived neural stem cells quickly incorporate into neurons and microglia in 5xFAD mice.
Front Aging Neurosci. 2023 Jun 22;15:1200445. doi: 10.3389/fnagi.2023.1200445. eCollection 2023.
8
Generation of Lens Progenitor Cells and Lentoid Bodies from Pluripotent Stem Cells: Novel Tools for Human Lens Development and Ocular Disease Etiology.
Cells. 2022 Nov 6;11(21):3516. doi: 10.3390/cells11213516.
9
Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies.
Blood. 2023 Feb 23;141(8):846-855. doi: 10.1182/blood.2022016205.
10
Stem cell-based therapy for pulmonary fibrosis.
Stem Cell Res Ther. 2022 Oct 4;13(1):492. doi: 10.1186/s13287-022-03181-8.
本文引用的文献
1
A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog.
Cell Stem Cell. 2009 Nov 6;5(5):491-503. doi: 10.1016/j.stem.2009.09.012. Epub 2009 Oct 8.
2
Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells.
Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15720-5. doi: 10.1073/pnas.0908450106. Epub 2009 Sep 8.
3
Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells.
J Cell Sci. 2009 Oct 1;122(Pt 19):3502-10. doi: 10.1242/jcs.054783. Epub 2009 Sep 1.
4
Generation of pluripotent stem cells from patients with type 1 diabetes.
Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15768-73. doi: 10.1073/pnas.0906894106. Epub 2009 Aug 31.
5
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs.
Nature. 2009 Sep 17;461(7262):402-6. doi: 10.1038/nature08320. Epub 2009 Aug 19.
6
Adult mice generated from induced pluripotent stem cells.
Nature. 2009 Sep 3;461(7260):91-4. doi: 10.1038/nature08310.
7
iPS cells produce viable mice through tetraploid complementation.
Nature. 2009 Sep 3;461(7260):86-90. doi: 10.1038/nature08267.
8
Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells.
Nat Genet. 2009 Sep;41(9):968-76. doi: 10.1038/ng.428. Epub 2009 Aug 9.
9
The role of environmental mercury, lead and pesticide exposure in development of amyotrophic lateral sclerosis.
Neurotoxicology. 2009 Sep;30(5):761-5. doi: 10.1016/j.neuro.2009.07.010. Epub 2009 Jul 24.
10
iPS cells can support full-term development of tetraploid blastocyst-complemented embryos.
Cell Stem Cell. 2009 Aug 7;5(2):135-8. doi: 10.1016/j.stem.2009.07.001. Epub 2009 Jul 23.
Zotero 插件